To study the visual and angiographic outcome of eyes with neovascular age-related macular degeneration associated with pigment epithelium detachment (PED) treated by photodynamic therapy. Methods: Review of the medical charts and the fluorescein and indocyanine green angiograms of all consecutive patients with age-related macular degeneration associated with choroidal neovascularization and serous PED of at least 1 disc diameter, who received photodynamic therapy from January 1, 2000, to August 31, 2002. Results: Thirty patients (34 eyes) met the study criteria. Each underwent 1 to 8 treatments (mean, 4); duration of follow-up was 12 to 36 months (mean, 19 months). Nineteen eyes (56%) lost 3 or more Snellen lines of vi
Background-Diabetic macular oedema is the leading cause ofvision deterioration in diabetic retinopathy. Extracelilular fluid within the retina, which distorts the retinal architecture, was assumed to be strictly of retinal vasculature origin.
• PURPOSE: To evaluate the visual outcome of patients with subfoveal choroidal neovascularization due to agerelated macular degeneration, who received photodynamic therapy (PTD) in a clinical setting and to identify potential predictive visual and angiographic factors.• DESIGN: Interventional case series.• METHODS: The study included 74 patients with subfoveal choroidal neovascularization who underwent PDT from January 2000 to March 2001 and completed at least 1 year follow-up. All patients received verteporfin PDT and were followed clinically, with fluorescein angiography (74 eyes), and with indocyanine green angiography (65 eyes). A review of the medical records and angiograms was performed.• RESULTS: Mean follow-up was 15.6 months. Patients received a mean of 3.4 treatments per year. Sixty-six percent lost less than 3 Snellen lines of visual acuity. Three patients (4%) experienced profound visual acuity loss to finger counting. Final visual acuity was positively correlated with lesion size and visual acuity at presentation. Visual outcome was worse in the presence of cystoid macular edema. On indocyanine green angiography, a round hypofluorescent spot was seen at the site of the PDT, with maintenance of medium and large choroidal vessels.• CONCLUSION: Smaller lesion size and better visual acuity at presentation were good predictive signs, whereas cystoid macular edema was found to be a poor A GE-RELATED MACULAR DEGENERATION IS THE LEADing cause of legal blindness in white persons aged 50 years and older in the United States, with choroidal neovascularization accounting for the majority of cases. [1][2][3] Photodynamic therapy (PDT) has been reported to result in vaso-occlusion of choroidal neovascularization, with minimal effect on the sensory retina and the retinal pigment epithelium. 4 The Treatment of Age-Related Macular Degeneration With PDT (TAP) Study Group 5,6 concluded that PDT is a safe and effective mode of treatment for patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration.The purpose of this retrospective study was to evaluate the visual acuity of patients with subfoveal choroidal neovascularization caused by age-related macular degeneration after administration of PDT in a clinical setting. We also sought to identify possible predictive visual and angiographic factors for the outcome of this treatment.
METHODSTHE STUDY WAS CONDUCTED AT OUTPATIENT OPHTHALmology clinics in a university-affiliated medical institution. We reviewed the clinical charts and fluorescein and indocyanine green angiographies of 74 consecutive patients with subfoveal choroidal neovascularization due to age-related macular degeneration who were treated with verteporfin PDT from
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.